 Sydney, AUSTRALIA, March 16, 2021 GLOBE NEWSWIRE -- Immutep Limited ASX: IMM; NASDAQ: IMMP Immutep or the Company, a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, announces a second clinical trial collaboration and supply agreement with subsidiaries of Merck Co., Inc., Kenilworth, NJ, USA known as MSD outside the United States and Canada. Under the agreement, Immutep will conduct a new Phase IIb clinical trial in 1st line HNSCC patients, as initially described in the ASX announcement dated 28 September 2020. 